Clinical Summary: 

• Design/Population: In this randomized phase 2 trial, patients with platinum-eligible relapsed ovarian cancer and high FRα expression received carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine maintenance or standard platinum-based doublet chemotherapy followed by PARP inhibitor maintenance when applicable.
• Key Outcomes: The addition of mirvetuximab soravtansine to carboplatin did not improve progression-free survival compared with standard platinum-based chemotherapy combinations.
• Clinical Relevance: These findings indicate that carboplatin plus MIRV did not provide a progression-free survival advantage in platinum-eligible relapsed ovarian cancer despite prior evidence of mirvetuximab soravtansine activity in platinum-resistant disease.

Results from the phase 2 MIROVA/AGO-OVAR 2.34 trial demonstrated that carboplatin plus mirvetuximab soravtansine did not improve progression-free survival (PFS) compared with standard platinum-based chemotherapy among patients with platinum-eligible relapsed ovarian cancer with high folate receptor alpha (FRα) expression.

These results were presented by Philipp Harter, MD, PhD, Ev. Kliniken Essen-Mitte, Essen, Germany, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. 

In this trial, 145 patients who had a platinum-free interval >3 months were randomized to receive either 6 cycles of carboplatin (AUC5) plus mirvetuximab soravtansine (6 mg/kg; adjusted by ideal body weight) once every 3 weeks followed by mirvetuximab soravtansine maintenance or carboplatin plus paclitaxel, gemcitabine, or pegylated liposomal doxorubicin followed by maintenance PARP inhibitor therapy when applicable. Patients were stratified based on BRCA-status, platinum-free interval, and number of prior lines of chemotherapy. The primary end point was PFS.

At analysis, median PFS was 9.53 months in the mirvetuximab soravtansine arm and 9.79 months in the standard arm (hazard ratio [HR], 1.00; 95% confidence interval [CI], 0.68 to 1.46; P = .996).

“MIROVA/AGO-OVAR 2.34 is the first randomized trial evaluating the activity and safety of the combination of carboplatin with an antibody-drug conjugate in the setting of platinum-eligible relapsed ovarian cancer,” concluded Dr Harter. “The primary end point regarding improvement of PFS was not met… [and further analysis will be presented].” 

Source:

Harter P, Heitz F, Marmé F, et al. A randomized phase II trial of mirvetuximab soravtansine in folate receptor alpha (FRα)–high recurrent ovarian cancer eligible for platinum-based chemotherapy (MIROVA/AGO-OVAR 2.34). Presented at the ASCO Annual Meeting. May 29 - June 2, 2026. Chicago, Illinois. Abstract 5506.